Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance

Lancet Infectious Diseases

Volumn 1, Issue 3, 2001, Pages 147-155

  Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PEPTIDOGLYCAN; PEPTIDYLTRANSFERASE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; CELL WALL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; MICROBIOLOGY; PHYSIOLOGY; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CELL WALL; HUMANS; MODELS, MOLECULAR; PEPTIDOGLYCAN; PEPTIDYL TRANSFERASES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0035495687     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00091-3     Document Type: Review

References (50)

1. Jevons M.P. "Celbenin"-resistant staphylococci. BMJ. 1:1961;124-125.
2. Chambers H.F. The changing epidemiology of Staphylococcus aureus. Emerg Infect Dis. 7:2001;178-182.
3. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
4. Hiramatsu K., Aritaka N., Hanaki H., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 350:1997;1668-1671.
5. Tenover F.C., Lancaster M.V., Hill B.C., et al. Characterization of staphylococci with reduced susceptibility to vancomycin and other glycopeptide. J Clin Microbiol. 36:1998;1020-1027.
6. Ploy M.C., Grelaud C., Martin C., de Lumley L., Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 351:1998;1212.
7. Kim M.-N., Pai C.H., Woo J.H., Ryu J.S., Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol. 38:2000;3879-3881.
8. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 340:1999;493-501.
9. Ferraz V., Duse A.G., Kassel M., Black A.D., Ito T., Hiramatsu K. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S Afr Med J. 90:2000;1113.
10. Chesneau O., Morvan A., El Solh N. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospital. J Antimicrob Chemother. 45:2000;887-890.
11. Hood J., Edwards G.F.S., Cosgrove B., Curran E., Morrison D., Gemmell C.G. Vancomycin-intermediate Staphylococcus aureus at a Scottish hospital. J Infect. 40:2000;A11.
12. Marchese A., Balistreri G., Tonoli E., Debbia E.A., Schito G.C. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol. 38:2000;866-869.
13. Rotun S.S., McMath V., Schoonmaker D.J., et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis. 5:1999;147-149.
14. Geisel R., Schmitz F.J., Thomas L., et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J Antimicrob Chemother. 43:1999;846-848.
15. Bierbaum G., Fuchs K., Lenz W., Szekat C., Sahl H.G. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis. 18:1999;691-696.
16. Trakulsomboon S., Danchaivijitr S., Rongrungruang Y., et al. The first report on methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol. 39:2001;591-595.
17. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resistance Updates. 1:1998;135-150.
18. Reynolds P.E., Brown D.F.J. Penicillin-binding protiens of beta-lactam-resistant strains of Staphylococcus aureus. FEBS Lett. 192:1985;28-32.
19. Utsui Y., Yokota T. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 28:1985;397-403.
20. Hartman B.J., Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol. 158:1984;513-516.
21. Katayama Y., Ito T., Hiramatsu K. A new class of genetic element, Staphylococcus Cassette Chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 44:2000;1549-1555.
22. Hanaki H., Kuwahara-Arai K., Boyle-Vavra S., Daum R.S., Labischinski H., Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. Antimicrob Chemother. 42:1998;199-209.
23. Hanaki H., Labischinski H., Inaba Y., Kondo N., Murakami H., Hiramatsu K. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother. 42:1998;315-320.
24. Cui L., Murakami H., Kuwahara-Arai K., Hanaki H., Hiramatsu K. Contribution of a thickened cell wall and its gultamine non-amidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother. 44:2000;2276-2285.
25. Sieradzki K., Roberts R.B., Haber S.W., Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med. 340:1999;517-523.
26. Sieradzki K., Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol. 181:1999;7566-7570.
27. Sieradzki K., Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:1997;2557-2566.
28. Kuroda M., Kuwahara-Arai K., Hiramatsu K. Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem Biophys Res Commun. 269:2000;485-490.
29. Kuroda M., Ohta T., Uchiyama I., et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet. 357:2001;1225-1240.
30. Bobin-Dubreux S., Reverdy M.E., Nervi C., et al. Clinical isolate of vancomycin-hetero intermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin- resistant derivative. Antimicrob Agents Chemother. 45:(1):2001;349-352.
31. Kaatz G.W., Seo S.M., Dorman N.J., Lerner S.A. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis. 162:1990;103-108.
32. Brunet G., Vedal G., Dreyfus F., et al. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicaemia who recovered after administration of vancomycin. Eur J Clin Microb Infect Dis. 9:1990;145-147.
33. Shlaes D.M., Shlaes J.H., Vincent S., Etter L., Fey P.D., Goering R.V. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrob Agents Chemother. 37:1993;2432-2437.
34. Hanaki H., Hiramatsu K. Detection methods of glycopeptide-resistant Staphylococcus aureus I: Susceptibility testing. Gillespie S.H. Antibiotic resistance methods and protocol Totowa. 2001;85-92 Humana Press, New Jersey.
35. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med. 104:1998;7S-10S.
36. Boyle-Vavra S., Berke S.K., Lee J.C., Daum R.S. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 44:2000;272-277.
37. Tanaka T., Okuzumi K., Iwamoto A., Hiramatsu K. A retrospective study on methicillin-resistant Staphylococcus aureus clinical strains in Tokyo University Hospital. J Infect Chemother. 1:1995;40-49.
38. Lipsitch M., Bergstrom C.T., Levin B.R. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci U S A. 97:2000;1938-1943.
39. Asada K., Inaba Y., Tateda-Suzuki E., Kuwahara-Arai K., Ito T., Hiramatsu K. Evolution and resistance expression of MRSA; evaluation of beta-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression. Acta Biochim Pol. 42:1995;517-524.
40. Hiramatsu K., Ito T., Hanaki H. Evolution of methicillin and glycopeptide resistance in Staphylococcus aureus. Finch R.G., Williams R.J. Bailliere's Clinical Infectious Disease. 1999;221-242 Bailliere Tindall, London.
41. Kondo N., Kuwahara-Arai K., Kuroda-Murakami H., Tateda-Suzuki E., Hiramatsu K. Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control. Antimicrob Agents Chemother. 45:2001;815-824.
42. Aritaka N., Hanaki H., Cui L., Hiramatsu K. The combination effect of vancomycin and beta-lactams against Staphylococcus aureus strain Mu3 with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother. 45:2001;1292-1294.
43. Hanaki H., Hiramatsu K. Combination effect of teicoplanin and various antibiotics against hetero-VRSA and VRSA. Kansenshogaku Zasshi. 73:1999;1048-1053.
44. Pittet D., Hugonnet S., Harbarth S., Mourouga P., Sauvan V., Touveneau S. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet. 356:2000;1307-1312.
45. Kuramoto S., Kizu J., Yamamoto K. Appropriate and restricting antibiotics prescribing to combat VRE and VRSA. Antibiot Chemother. 15:1999;91-97.
46. Chambers H.F., Kartalija M., Sande M. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J Infec Dis. 171:1995;897-902.
47. Tanaka M., Wada N., Mori-Kurosaka S., Chiba M., Sato K., Hiramatsu K. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin. J Antimicrob Chemother. 42:1998;552-553.
48. Backo M., Gaenger E., Burkart A., Chai Y.L., Bayer A.S. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam. Antimicrob Agents Chemother. 43:1999;2565-2568.
49. Kato D, Ito T, Imai D, Hiramatsu K. In vitro synergy between linezolid and sulbactam/ampicillin against methicillin-resistant Staphylococcus aureus clinical isolates including those with reduced susceptibility to vancomycin. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000; Abstract no. 2297.
50. Chambers H.F., Sachdeva M. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis. 161:1990;1170-1176.